Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Adam C Berger, MD, FACS
Rutgers Cancer Institute of New Jersey
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Laura & Isaac Perlmutter Cancer Center at Nyu Langone Health
New York, New York, United States
- Nyu Langone Medical Center (tisch Hospital)
New York, New York, United States
- New York University Langone Medical Center
New York, New York, United States
- Duke University Medical Center - Duke Cancer Center
Durham, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2020
- Primary completion
- 28 Mar 2025
- Completion
- 28 Mar 2025
- Last update posted
- 23 Jan 2026
- Registered enrollment
- 5
- Registry id
- NCT04163952
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.